Cibc World Markets Corp Purchases 3,164 Shares of ResMed Inc. (NYSE:RMD)

Cibc World Markets Corp boosted its position in ResMed Inc. (NYSE:RMD - Free Report) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,141 shares of the medical equipment provider's stock after acquiring an additional 3,164 shares during the quarter. Cibc World Markets Corp's holdings in ResMed were worth $5,292,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC boosted its position in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 110 shares during the period. OFI Invest Asset Management purchased a new stake in ResMed during the fourth quarter valued at about $39,000. BankPlus Trust Department purchased a new stake in ResMed during the fourth quarter valued at about $44,000. Rosenberg Matthew Hamilton purchased a new stake in ResMed during the fourth quarter valued at about $54,000. Finally, SBI Securities Co. Ltd. purchased a new stake in ResMed during the fourth quarter valued at about $67,000. Institutional investors own 54.98% of the company's stock.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $227.71, for a total transaction of $455,420.00. Following the completion of the transaction, the director now owns 75,218 shares of the company's stock, valued at approximately $17,127,890.78. This trade represents a 2.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares of the company's stock, valued at $2,327,289.75. This represents a 50.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,940 shares of company stock valued at $9,164,385. Corporate insiders own 0.71% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have issued reports on RMD shares. The Goldman Sachs Group started coverage on shares of ResMed in a research report on Thursday, January 16th. They set a "buy" rating for the company. Morgan Stanley started coverage on shares of ResMed in a research report on Wednesday. They set an "overweight" rating and a $280.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Saturday, March 15th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.83.

ResMed Stock Down 0.6 %

RMD traded down $1.35 on Friday, hitting $219.77. The company had a trading volume of 1,171,311 shares, compared to its average volume of 959,797. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed Inc. has a 52-week low of $172.19 and a 52-week high of $263.05. The stock has a fifty day simple moving average of $234.91 and a 200-day simple moving average of $239.02. The firm has a market capitalization of $32.28 billion, a P/E ratio of 25.95, a P/E/G ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, equities analysts expect that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were issued a $0.53 dividend. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.96%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.